Bolstering its position in the travel vaccines market, as well as its cash balance, Crucell NV completed the acquisition of SBL Vaccin AB for €39.4 million (US$51.9 million) cash and raised €80 million through a new share issue. (BioWorld International)
Bolstering its position in the travel vaccines market, as well as its cash balance, Crucell NV completed the acquisition of SBL Vaccin AB for €39.4 million (US$51.9 million) cash and raised €80 million through a new share issue. (BioWorld International)
Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to acquire CoTherix Inc. for $13.50 per share, or about $420 million. (BioWorld International)
Broadening its footprint in its key market of pulmonary arterial hypertension (PAH), while reducing its dependence on its Tracleer (bosentan) franchise, Actelion Ltd. entered a definitive agreement to acquire CoTherix Inc. for $13.50 per share, or about $420 million. (BioWorld International)
